Skin Lymphomas

This case series study examines the association between APOA5 and APOC3 polymorphisms and triglyceride levels in patients with cutaneous T-cell lymphoma before, during, and after treatment with bexarotene.

This randomized clinical trial assesses whether treatment with the neurokinin 1 receptor antagonist aprepitant decreases pruritus vs placebo in patients with Sézary syndrome.

This preclinical in vitro study identifies novel small molecules that induce extrinsic apoptosis and serve as an alternative treatment for cutaneous T-cell lymphoma.

This virological study examines the association of cutavirus DNA with different types of cutaneous B-cell lymphoma and cutaneous T-cell lymphoma in lesional skin samples.

This case series examines the characteristics of cutaneous T-cell lymphoma associated with hemophagocytic lymphohistiocytosis and analyzes the presenting signs and symptoms, therapeutic options, and outcomes.

This case series describes the occurrence of graft-vs-host-disease (GVHD) in patients with cutaneous T-cell lymphomas (CTCLs) treated with the CC chemokine receptor 4 (CCR4) antibody mogalizumab prior to allogeneic hematopoietic stem cell transplantation (HSCT).

This case report describes a patient with cutaneous T-cell lymphoma who developed methotrexate-associated B-cell lymphoproliferative disease.

This case report describes the treatment of CD30-negative refractory mycosis fungoides with brentuximab vedotin.

This phase 2 trial of 12 patients assesses the efficacy and safety of brentuximab vedotin for lymphomatoid papulosis.

This phase 1-2 trial evaluates the use of combination therapy with O⁶-benzylguanine and carmustine to determine the maximum tolerated dose in patients with stage IA or stage IIA cutaneous T-cell lymphoma, mycosis fungoides type.

This case report describes a case of cutaneous gamma-delta T-cell lymphoma successfully treated with brentuximab vedotin.

This study examines a cohort of 203 patients with folliculotropic mycosis fungoides (FMF) and differentiates between indolent and aggressive FMF using clinicopathological criteria.

This phase 2 clinical trial assesses the efficacy and safety of APO866 in patients with refractory or relapsed cutaneous T-cell lymphoma.

This case report describes an occurrence of cutaneous T-cell lymphoma misdiagnosed as lipodermatosclerosis.

This case series of 7 patients describes the use of low-dose, high dose-rate brachytherapy in the treatment of cutaneous T-cell lymphoma.